Ikarian Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Ikarian Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-40,000	Closed	-$11.3M	–	160
2022 Q2	$11.3M	Buy	40,000 +15,000	+60%	+$4.01M	2.06%	15
2022 Q1	$6.52M	Buy	+25,000	New	+$5.93M	0.86%	33

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ikarian Capital's VRTX Position: Q3 2022 in Review

Ikarian Capital sold out of Vertex Pharmaceuticals (VRTX) in Q3 2022, closing a stake of 40,000 shares — an estimated $11.3M sold.

Ikarian Capital first reported a position in VRTX in Q1 2022 and held it in 2 quarters. The position peaked at $11.3M in Q2 2022. 1,124 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

Ikarian Capital reported no remaining Vertex Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Ikarian Capital sold 40,000 Vertex Pharmaceuticals shares in Q3 2022, an estimated $11.3M.
Ikarian Capital first reported a position in Vertex Pharmaceuticals in Q1 2022 and held it in 2 quarters.
Ikarian Capital's Vertex Pharmaceuticals position peaked at $11.3M in Q2 2022.
1,124 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.